Neuphoria Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Neuphoria Therapeutics (NEUP) with a Buy rating and $81 price target The company is developing BNC210 to treat social anxiety disorder episodically, the analyst tells investors in a research note. The firm says that with no agent approved for the acute treatment of anxiety attacks in a social situation, BNC210 offers a “best- and first-in-class” profile.